[go: up one dir, main page]

NO20001514L - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist

Info

Publication number
NO20001514L
NO20001514L NO20001514A NO20001514A NO20001514L NO 20001514 L NO20001514 L NO 20001514L NO 20001514 A NO20001514 A NO 20001514A NO 20001514 A NO20001514 A NO 20001514A NO 20001514 L NO20001514 L NO 20001514L
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
osteoporosis
useful
Prior art date
Application number
NO20001514A
Other languages
Norwegian (no)
Other versions
NO20001514D0 (en
Inventor
Dirk Andries Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001514D0 publication Critical patent/NO20001514D0/en
Publication of NO20001514L publication Critical patent/NO20001514L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En forbindelse med formel (I) er beskrevet, som er en vitronectin-reseptor- antagonist og er nyttig for behandling av osteoporose, eller et farmasøytisk godtagbart salt derav.A compound of formula (I) is disclosed which is a vitronectin receptor antagonist and useful for the treatment of osteoporosis, or a pharmaceutically acceptable salt thereof.

NO20001514A 1997-09-24 2000-03-23 Vitronectin receptor antagonist NO20001514L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
PCT/US1998/019949 WO1999015170A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001514D0 NO20001514D0 (en) 2000-03-23
NO20001514L true NO20001514L (en) 2000-03-23

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001514A NO20001514L (en) 1997-09-24 2000-03-23 Vitronectin receptor antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (en)
JP (1) JP2002528380A (en)
KR (1) KR20010024247A (en)
CN (1) CN1273529A (en)
AU (1) AU9577498A (en)
BR (1) BR9813208A (en)
CA (1) CA2303846A1 (en)
HU (1) HUP0003949A2 (en)
IL (1) IL135189A0 (en)
NO (1) NO20001514L (en)
PL (1) PL339413A1 (en)
TR (1) TR200000792T2 (en)
WO (1) WO1999015170A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
WO2002018377A1 (en) * 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
KR20030027106A (en) * 2000-08-30 2003-04-03 파마시아 코포레이션 Gem-substituted alpha v beta 3 integrin antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
JP4660067B2 (en) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy using an anti-angiogenic agent and TNFα
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PT2101805E (en) 2007-01-18 2013-01-31 Merck Patent Gmbh Integrin ligands for use in treating cancer
KR101588469B1 (en) 2007-11-16 2016-01-25 우베 고산 가부시키가이샤 Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
CA2757396A1 (en) 2009-03-30 2010-10-07 Ube Industries, Ltd. Medical composition for treatment or prophylaxis of eye diseases
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
EA201101651A1 (en) 2009-05-25 2012-08-30 Мерк Патент Гмбх CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT
CN103864765B (en) * 2014-03-05 2016-02-10 天津药物研究院 Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
JP6649902B2 (en) 2014-05-30 2020-02-19 ファイザー・インク Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vitronectin receptor antagonists
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
WO1998015278A1 (en) * 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation

Also Published As

Publication number Publication date
WO1999015170A1 (en) 1999-04-01
AU9577498A (en) 1999-04-12
EP1017387A1 (en) 2000-07-12
KR20010024247A (en) 2001-03-26
JP2002528380A (en) 2002-09-03
PL339413A1 (en) 2000-12-18
IL135189A0 (en) 2001-05-20
CA2303846A1 (en) 1999-04-01
BR9813208A (en) 2000-08-22
NO20001514D0 (en) 2000-03-23
TR200000792T2 (en) 2000-09-21
EP1017387A4 (en) 2004-08-18
HUP0003949A2 (en) 2001-10-28
CN1273529A (en) 2000-11-15

Similar Documents

Publication Publication Date Title
NO20001514L (en) Vitronectin receptor antagonist
NO983002L (en) Vitronectin receptor antagonists
NO20001515L (en) Vitronectin receptor antagonist
DK0894084T3 (en) Cinnamic acid derivatives and their use as integrin antagonists
GB0111523D0 (en) Chemical compounds
NO20025821L (en) 2-aminocarbonyl-9H-purine
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
TR199801253T2 (en) Vitronectin receptor antagonists.
MXPA04004674A (en) Cannabinoid receptor ligands.
PT923554E (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
NO975975L (en) Vitronectin receptor antagonists, preparation and use thereof
DE60121461D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
ATE240339T1 (en) NUCLEOTIDE ANALOGUES
BR9812340A (en) Vitronectin receptor antagonists
DK1119359T3 (en) 2-methyl-thieno-benzodiazepine formulation
NO973652D0 (en) 5- (4-Subst. Piperidinyl-1) -3-aryl pentanoic acid and derivatives as tachykinin receptor antagonist
NO974400L (en) Combination preparations containing benazepril or benazeprilat and valsartan
AP1534A (en) Vitronectin receptor antagonists.
NO20014855D0 (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
NO963331L (en) 5-Heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
DK1204658T3 (en) Benzofurylpiperazine-serotonin agonists
NO990914L (en) Amorphous benzothiophenes, methods of preparation and methods of use
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
WO2000007544A3 (en) Vitronectin receptor antagonists
NO306673B1 (en) Intermediate for the preparation of pharmaceutically active compound

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application